Pityriasis rosea–like eruption during treatment with imatinib mesylate: Description of 3 cases - 21/08/11
, Francesca Prestinari, MD a, Elena Roveda, MD a, Tania Barbagallo, MD a, Eleonora Bellani, MD a, Camilla Vassallo, MD a, Ester Orlandi, MD b, Francesco Passamonti, MD b, Giovanni Borroni, MD a
Reprint requests: Valeria Brazzelli, MD, Department of Human and Hereditary Pathology, Institute of Dermatology, University of Pavia, IRCCS-Policlinico S. Matteo, Piazza C. Golgi, 2, 27100 Pavia, ITALY.Pavia, Italy
Abstract |
Imatinib mesylate (IM) represents the first-line treatment for chronic myeloid leukemia (CML). We hereby relate 3 cases of an IM-induced pityriasis rosea (PR)-like cutaneous eruption. Patients developed an erythematous, slightly pruritic, macular skin eruption, with many lesions having a peripheral collarette of desquamation, confined to the trunk, limbs, and arms with a vaguely dermatomal diffusion. The histologic findings suggested a reactive process to the drug. Full dermatological recovery was obtained after IM discontinuation, but lesions reappeared upon restoring therapy, suggesting the drug-related nature of the rash. To our knowledge this is the first reported PR-like cutaneous eruption to IM.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by Stiefel Laboratories. Funding sources: None. Conflicts of interest: None identified. |
Vol 53 - N° 5S
P. S240-S243 - novembre 2005 Retour au numéro
Article précédent
- Association of palmoplantar keratoderma, cutaneous squamous cell carcinoma, dental anomalies, and hypogenitalism in four siblings with 46,XX karyotype: A new syndrome
- Giuseppe Micali, Maria Rita Nasca, Daniele Innocenzi, Lucretia A. Frasin, Orietta Radi, Pietro Parma, Giovanna Camerino, Robert A. Schwartz
- Annular elastolytic giant cell granuloma in an infant: Improvement after treatment with oral tranilast and topical pimecrolimus
- Hae-Woong Lee, Mi-Woo Lee, Jee-Ho Choi, Kee-Chan Moon, Jai-Kyoung Koh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?